ESSA Pharma Inc. reported earnings results for the fourth quarter ended September 30, 2023. For the fourth quarter, the company reported net loss was USD 5.48 million compared to USD 6.32 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.14 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.47 USD | +0.74% | -5.20% | -17.12% |
May. 20 | Top Premarket Decliners | MT |
May. 14 | ESSA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.12% | 243M | |
+49.21% | 56.87B | |
+36.33% | 39.72B | |
-6.86% | 39.27B | |
-4.42% | 28.73B | |
+12.00% | 26.21B | |
-18.27% | 19.79B | |
+29.57% | 12.28B | |
+25.41% | 12.23B | |
-0.35% | 12.12B |
- Stock Market
- Equities
- EPIX Stock
- News ESSA Pharma Inc.
- ESSA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023